Walk in interview in Quality Control, Quality Assurance, Production, Microbiology at Glenmark
Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries. It has twelve manufacturing facilities in four countries and has five R&D centres.
AIIMS Bhopal is one of the seven AIIMS apex healthcare institutes being established by the Ministry of Health & Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna(PMSSY).
The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group. Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.
.png)
